A circuit used to track ultrasound signals is at the heart ofa patent dispute between ATL and SRI International of Palo Alto,CA. ATL, headquartered in Bothell, WA, manufactures and distributesfour ultrasound systems in the Ultramark series. At issue
A circuit used to track ultrasound signals is at the heart ofa patent dispute between ATL and SRI International of Palo Alto,CA.
ATL, headquartered in Bothell, WA, manufactures and distributesfour ultrasound systems in the Ultramark series. At issue aretracking filter circuits in the Ultramark 4 and two discontinuedproducts, the Ultramark 5 and ADR 4000. The vendor's main product,its high-end Ultramark 9 radiology scanner, does not use the disputedcircuit.
SRI filed a request for partial summary judgment on its patentinfringement claim in July 1991. Last November, a district courtruled on that motion and determined ATL had infringed SRI's patent.
ATL is pursuing an appeal through the federal circuit courtin Washington, DC.
"We believe there is prior art here, based on two priorpatents issued to other companies that have since expired,"said Anne Bugge, director of corporate and investor relationsfor ATL. "We don't believe that SRI has a valid patent orthat we have infringed."
While ATL's appeal is pending, the district courts have continuedto entertain motions relating to the summary judgment. Late lastmonth, U.S. District Court Judge Stanley A. Weigel entered aninjunction enjoining ATL from continued use of the circuit forthe remaining 10 months left on SRI's patent.
The effective date of the injunction has been stayed untilJune, however, Bugge said.
"The stay is to give ATL time to remove the disputed circuitwithout interrupting delivery to customers," she said. "We'reconfident we will be able to complete an engineering program todo that."
SRI has also asked for $5 million in damages resulting fromthe patent infringement. A jury trial is scheduled for May.
It is not known whether the appeal will be granted before thedamages trial. But ATL is already committed to appeal should anadverse decision result from the trial, she said.
"We want people to know we believe this case is withoutmerit, it has no impact on our customers, and that we are appealingthese determinations," she said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.